In plain terms

The claim being assessed: Clinically supervised retatrutide causes clinically meaningful weight loss in adults meeting the registered obesity-trial eligibility criteria.

Where the evidence stands: Ε — Causal in a specific setting. It genuinely causes the effect in one well-defined situation, but that does not extend to the wider claim.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: The registered primary subclaim SC2 supports Ε with Moderate confidence. Retatrutide causes substantial weight loss under supervised trial conditions. Human receptor partition, superiority to modern active comparators and equivalence of online vials require separate evidence. Multiple trials replicate the pharmacological effect; they do not automatically constitute independent causal lines under the frozen shared-failure definition.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Leading among models compared

What this review means

Retatrutide causes substantial weight loss in supervised trials; superiority to modern obesity drugs and equivalence of online research vials remain unestablished in this review.

Implications for health and treatment: The registered primary subclaim SC2 supports Ε with Moderate confidence. Retatrutide causes substantial weight loss under supervised trial conditions. Human receptor partition, superiority to modern active comparators and equivalence of online vials require separate evidence. Multiple trials replicate the pharmacological effect; they do not automatically constitute independent causal lines under the frozen shared-failure definition.

Limits for individual care: 60 primary reports with 5 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 60 primary reports; claims: 65; verified: 65; unverified: 0. Verification is bounded attribution. Access: 5 partial-body and 55 bounded abstract/status examinations. Literature cutoff: 2026-10-12; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 6 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Retatrutide causes substantial weight loss in supervised trials; superiority to modern obesity drugs and equivalence of online research vials remain unestablished in this review.

Deciding experiment: A blinded randomized retatrutide versus contemporary obesity-dose dual/GLP1 comparator trial, matched eligibility, lifestyle support and treatment-regimen estimand over 72 weeks, with a prespecified retatrutide continuation-versus-withdrawal phase in baseline-defined tolerators and independent weight/function assessment. Add human energy-expenditure/intake/body-composition substudy without interpreting correlations as receptor necessity.

Belief versus evidence: The registered primary subclaim SC2 supports Ε with Moderate confidence. Retatrutide causes substantial weight loss under supervised trial conditions. Human receptor partition, superiority to modern active comparators and equivalence of online vials require separate evidence. Multiple trials replicate the pharmacological effect; they do not automatically constitute independent causal lines under the frozen shared-failure definition.

Best-supported rival: GLP1-based appetite suppression produces clinical weight loss (Ε) — the best-supported model that is not the nominal, resting on the STEP placebo, active-comparator and withdrawal trials, which show that single GLP-1 receptor agonism can produce meaningful weight loss without triple receptor agonism. The nominal, supervised retatrutide exposure producing clinical weight loss, still leads the tournament because it is the only model directly administering retatrutide; the rivals demonstrate alternative weight-loss routes, not that its effect is an artifact. A modern matched active-comparator and mechanistic partition trial would distinguish incremental benefit and receptor necessity.

COMPETING MECHANISTIC MODELS

Rank 1: Supervised retatrutide exposure produces clinical weight loss (Ε). Trial-quality retatrutide changes weight in baseline-defined adult obesity/overweight populations. Placebo and dulaglutide-controlled retatrutide phase 2 studies plus subsequent phase 3 evidence demonstrate the drug effect. Three-receptor human necessity, modern active superiority and every dose/context are not established.

Rank 2: GLP1-based appetite suppression produces clinical weight loss (Ε). Single GLP1 receptor agonism can produce meaningful weight loss without triple receptor agonism. STEP placebo and active/withdrawal trials demonstrate semaglutide efficacy, maintenance sensitivity and dose effects. This does not show GLP1 alone explains all retatrutide benefit or its complete mechanism.

Rank 3: GIP/GLP1 dual agonism produces large clinical weight loss (Ε). Dual agonism can produce comparable-order clinical effects without glucagon agonism. SURMOUNT placebo, direct active comparison and withdrawal trials demonstrate tirzepatide clinical benefit. Comparable-order across trials is not equivalence; no direct retatrutide versus dual-agonist comparison was examined.

Rank 4: Energy-intake and behavioral intervention reduce weight without triagonism (Δ). Reduced intake and behavioral intervention provide a non-triple-receptor route to weight reduction. Intensive lifestyle/placebo arms and run-in weight changes in STEP-3/SURMOUNT-3 show measurable loss before added drug effects. Bundled behavior intervention and selected run-in cohorts do not isolate each component; trial weight effects exceed placebo rather than being explained away.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Clinically supervised retatrutide causes clinically meaningful weight loss in adults with obesity or overweight and a weight-related condition.

Evaluated wording: Clinically supervised retatrutide causes clinically meaningful weight loss in adults meeting the registered obesity-trial eligibility criteria. The original obesity/overweight eligibility wording is retained in preregistration. This grammatical restatement describes one baseline-defined adult population (BMI at least 30, or at least 27 with a weight-related condition), not two rival causal hypotheses. Dose, trial product and registered horizon are unchanged.

The nominal is the clinical sufficiency proposition represented by SC2. Mechanism, superiority, additional indication and safety subclaims are separately reported and do not gate the registered efficacy claim. The original topic family and this narrower gradeable restatement are retained; no response-based exclusions are allowed.

Selection: position 2 among the first five editorial traffic-priority families, registered on 2026-10-12. First five editorial traffic-priority families in health_topic_traffic_priority_2026-10-12/ranking.json; traffic proxies are not measured worldwide popularity or a preassigned verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: No shipped rubric directly covers obesity-drug efficacy. Rubric06 is the nearest metabolic route, with explicit clinical adaptation: a randomized specified drug exposure changing bodyweight and prespecified ≥5% responder outcomes is a field-valid clinical sufficiency perturbation. Lifespan extension is not required for this non-lifespan claim. Receptor engagement is not equivalent to receptor-specific human necessity; active-comparator superiority and product equivalence have independent evidence standards. The original v5.3 ladder, caps and verbatim rubric text remain unchanged.

The 2023 obesity phase 2 trial directly establishes a clinically meaningful weight-loss response: 338 randomized adults, placebo control and dose-dependent responses at 24 and 48 weeks. The 36-week diabetes phase 2 trial adds an active dulaglutide comparison and retains the low-dose weak/null response. These are genuine clinical successes, not merely shifts in metabolic biomarkers. The exact exposure, titration, estimand and eligibility determine their scope.

The 2026 evidence is materially newer than some provider summaries. TRANSCEND-T2D-1 adds 40-week randomized diabetes outcomes but enrolled BMI ≥23, so whole-cohort weight means do not exactly estimate the obesity/overweight subset. TRIUMPH-1 and TRIUMPH-2 were published 29 September 2026 and directly support substantial 80-week weight effects in non-diabetes and diabetes settings. Their longer endpoints corroborate the clinical picture without changing the preregistered 24–72-week gate. An inconsistent OSA sign in the indexed TRIUMPH-1 abstract is flagged and that number is not reproduced.

Mechanism is a different question. Original receptor/animal work establishes functional triagonist biology, and comparator experiments include receptor knockout and antagonist contrasts. Human retatrutide lipidomics and appetite substudies support mechanistic leads but cannot determine the necessity of all three receptors. In the appetite original body, aggregate appetite-weight correlations and several satiety/fullness contrasts are null. Diabetic and non-diabetic inflammatory outcomes also differ. These limits should accompany any claim that an entire metabolic pathway has been explained.

Retatrutide versus placebo, retatrutide versus dulaglutide 1.5 mg and retatrutide versus contemporary obesity-standard drugs are separate comparisons. SURMOUNT-5 directly demonstrates tirzepatide superiority to semaglutide under its regimen; it contains no retatrutide arm. Indirect comparisons and percentage rankings cannot transfer that randomization. Non-retatrutide polyagonists can cause weight loss without the same safety profile; NN1177 development stopped after original clinical safety signals.

Trial efficacy does not validate an unregulated product. The examined supply papers test semaglutide/liraglutide and simulated consumer tasks. They show credible quality/use failure modes while their limited samples and chemistry interpretation remain explicit. The JMIR abstract says endotoxin was detected in all samples, while the original Results report upper-bound values for two and a clear elevated value for one; the bounded review retains that detail. No directly tested retatrutide vial-to-clinical bridge was examined. Current FDA approval status is auxiliary regulatory context, not a trial-efficacy result.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The registered primary subclaim SC2 supports Ε with Moderate confidence. Retatrutide causes substantial weight loss under supervised trial conditions. Human receptor partition, superiority to modern active comparators and equivalence of online vials require separate evidence. Multiple trials replicate the pharmacological effect; they do not automatically constitute independent causal lines under the frozen shared-failure definition. Sensitivities: weakest-link Α; primary-subclaim Ε; scope-matched Ε.

Decisive-perturbation inventory and causal tally

[1] A 338-adult randomized placebo trial shows dose-related retatrutide weight loss through 48 weeks, with high-dose responder rates exceeding the registered 5% benchmark. Placebo efficacy is not superiority to semaglutide or tirzepatide; adverse GI events and heart-rate changes remain relevant.

[4] TRANSCEND-T2D-1 randomizes 537 adults and reports treatment-regimen weight loss of 11.5–15.3% versus 2.6% placebo at 40 weeks. Primary endpoint is HbA1c; entry BMI ≥23 includes participants outside the registered obesity/overweight scope, so whole-cohort means are corroboration with a population limitation.

[5] TRIUMPH-2 shows substantial placebo-adjusted weight loss in 1152 adults with BMI ≥27 and T2D using multiple-imputation treatment-regimen analyses. The 80-week endpoint extends beyond the registered 24–72-week horizon; no modern active comparator, and dysesthesia/hypotension/discontinuations qualify safety.

[6] Randomized double-dummy phase 2 T2D trial shows higher-dose weight loss beyond placebo and dulaglutide 1.5 mg through 36 weeks. Dulaglutide 1.5 mg is not modern obesity-dose semaglutide or tirzepatide; six inadvertent enrollments excluded from efficacy analyses; lower dose weak/null.

[47] SURMOUNT-5 directly randomizes tirzepatide versus semaglutide and demonstrates greater tirzepatide weight reduction at 72 weeks. Open-label active comparison and dose tolerability differ; this establishes their relationship, not retatrutide superiority.

[55] TRIUMPH-1 randomizes 2339 adults without diabetes and reports treatment-regimen weight reductions up to 25.0% versus 3.9% placebo at 80 weeks. Beyond the registered 24–72-week horizon; no active modern comparator; the original abstract contains an inconsistent OSA sign so that subgroup number is not repeated.

[56] Original LY3437943 discovery combines functional receptor assays, obese-mouse weight/energy experiments and early human pharmacokinetics/weight signals. Single-dose early human study is not 24–72-week efficacy or receptor-component necessity in humans; compound-specific mechanism needs matched counterfactuals.

[57] Original semaglutide test-purchase study finds mislabeled quantities, low measured purity and endotoxin detected in all three delivered vials, plus nondelivery scams. The highest-risk small-vendor sample, assay purity interpretation and the upper-bound form of two of the three endotoxin values all matter; this is not retatrutide testing or clinical population incidence.

Tally: 3 positive qualifying study units across scoped subclaims; 15 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Only direct positive retatrutide study units earn SC2 clinical crossing credit; comparator/class studies do not. 80-week results extend the registered horizon and are not needed to retrospectively redefine it. Original pooled reanalyses share parent-trial data; simulated supply tasks and biomarker analyses are not clinical efficacy crosses.

Cap audit, precedence and Β/Γ/Δ boundary

Positive placebo-controlled bodyweight change crosses the adapted clinical threshold for SC2 and is not Γ-capped as a biomarker. Animal/cell receptor results cross only their actual experimental scope; they cannot establish human component necessity or drug superiority (SC3). Lack of online product-linked evidence keeps SC4 unestablished without weakening trial efficacy. No weakest-evidence cap is applied to a complementary same-scope convergent set.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: All six rubric06 hard rules reviewed. Bodyweight is a clinical phenotype, so positive controlled weight outcomes are not biomarker-only findings. Lipid, inflammatory and neural readouts alone cannot prove clinical superiority, hard-event prevention or complete human receptor necessity. Single-species/class-mechanism evidence remains scoped; no lifespan criterion is imposed on this obesity-treatment claim.

SC3 cap: “Mechanistic plausibility plus one-species or in vitro support caps at Γ.” Direct animal/class polyagonist comparisons make incremental efficacy plausible, and retatrutide beats dulaglutide 1.5 mg in its specific diabetes phase 2 context. The reviewed evidence does not directly randomize retatrutide against contemporary obesity-dose semaglutide/tirzepatide for sustained outcomes. Across-trial percentages, structural statements and indirect comparisons cannot cross the registered human-superiority threshold.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Functional receptor assays and LY3437943 mouse pharmacology support in vivo engagement and cross the first perturbation threshold in that experimental setting. Human trial exposure and pharmacokinetics support plausibility, but receptor-by-receptor occupancy, energy expenditure and necessity at therapeutic human exposures are not directly partitioned. This is not a claim of demonstrated human three-receptor necessity.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Randomized trials show clinically meaningful weight loss in prespecified adult settings, including the 48-week obesity phase 2 study and the 36-week diabetes phase 2 study. Low doses do not uniformly exceed placebo, and doses and eligibility remain part of context. Additional 40-week diabetes phase 3 evidence and 80-week TRIUMPH results corroborate the effect but have distinct enrollment/horizon qualifications. Replicated same-modality RCTs raise confidence; comparator studies and secondary analyses do not create independent retatrutide causal lines.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Direct animal/class polyagonist comparisons make incremental efficacy plausible, and retatrutide beats dulaglutide 1.5 mg in its specific diabetes phase 2 context. The reviewed evidence does not directly randomize retatrutide against contemporary obesity-dose semaglutide/tirzepatide for sustained outcomes. Across-trial percentages, structural statements and indirect comparisons cannot cross the registered human-superiority threshold.

SC4 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. No directly examined product-linked retatrutide testing plus clinical evidence establishes that online research vials reproduce trial quality, efficacy and safety. Semaglutide/liraglutide analytical testing and a simulated preparation study identify relevant failure modes but cannot characterize every retatrutide vial. This positive equivalence proposition remains speculative; lack of approval and lack of evidence are not direct measurements of every product.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Assess functional receptor activation, specificity/antagonism or genetic perturbation, exposure and living-system phenotypes. Clinical pharmacokinetics do not prove the contribution of each receptor to patient weight loss.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): The applied clinical phenotype is percent bodyweight change and ≥5% responder status under randomized control in baseline-defined eligible adults at 24–72 weeks. Handle missingness, discontinuation, dose escalation and cointerventions explicitly; 80-week reports are additional evidence beyond the registered horizon.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): The registered clinical superiority threshold requires direct randomized comparable modern active treatment, population, dose and duration. Rodent comparison or indirect between-trial ranking does not satisfy it.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Equivalence requires batch-specific identity/content, contamination, formulation/route and exposure plus product-linked clinical outcomes. Regulatory classification and class-product findings are relevant context, not substitutes.

SC1 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Single-species or single-strain evidence” Clinical human sufficiency is explicitly adapted to the registered human endpoint. Mouse receptor results retain the tested species scope; they do not prove human receptor-by-receptor necessity.

SC1 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Applies to isolated metabolic biomarker inference; it cannot earn the clinical weight-loss threshold. Actual weight outcomes and living-system perturbations are assessed separately.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” Clinical human sufficiency is explicitly adapted to the registered human endpoint. Mouse receptor results retain the tested species scope; they do not prove human receptor-by-receptor necessity.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Applies to isolated metabolic biomarker inference; it cannot earn the clinical weight-loss threshold. Actual weight outcomes and living-system perturbations are assessed separately.

SC3 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Single-species or single-strain evidence” Clinical human sufficiency is explicitly adapted to the registered human endpoint. Mouse receptor results retain the tested species scope; they do not prove human receptor-by-receptor necessity.

SC3 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Applies to isolated metabolic biomarker inference; it cannot earn the clinical weight-loss threshold. Actual weight outcomes and living-system perturbations are assessed separately.

SC4 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Single-species or single-strain evidence” Clinical human sufficiency is explicitly adapted to the registered human endpoint. Mouse receptor results retain the tested species scope; they do not prove human receptor-by-receptor necessity.

SC4 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Applies to isolated metabolic biomarker inference; it cannot earn the clinical weight-loss threshold. Actual weight outcomes and living-system perturbations are assessed separately.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC1 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: no. Partition retatrutide receptor contributions at measured human exposures with matched mechanistic interventions and functional outcomes, not only receptor-binding estimates.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC2 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC2 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: no. Add a retatrutide-specific withdrawal/rechallenge or distinct validated natural/genetic/exposure line that fails differently from the initiation RCT modality, with comparable eligibility and prespecified weight outcomes. Replication alone improves confidence without adding an independence line.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Publish a direct randomized retatrutide versus obesity-standard semaglutide/tirzepatide comparison with matched estimands and sustained weight/function endpoints.

SC4 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Independently sample identified retatrutide supply batches, compare validated chemistry/sterility/exposure against trial-quality product and obtain lawful product-linked clinical evidence before claiming equivalence.

Upper ladder: Human therapeutic perturbation and dose-response are available for retatrutide, with extensive class comparator/withdrawal evidence. Retatrutide-specific withdrawal, independently failing natural/genetic lines and modern direct active comparison are not supplied by class studies. Clinical receptor necessity and long-term hard outcomes remain unresolved. Thus replicated RCT benefit is retained at Ε without inventing independence or unreachable-ladder rules.

Independence: All assigned models remain below Ζ. Retatrutide placebo/active-dose trials are replications of a pharmacological intervention modality; one common formulation/exposure or intervention-associated-bias failure could affect them. Secondary reports share parent trials. Rodent receptor perturbations and class-drug withdrawal inform alternatives but do not independently prove the exact registered human retatrutide claim. No different-lab or different-trial-count shortcut is used.

Falsification and pitfalls

Broad comparator-superiority and supply-equivalence inference fails its evidentiary test. No reviewed modern retatrutide active-comparator randomization or product-linked retail-equivalence data; positive placebo efficacy is insufficient for either. Additional downgrade: False.

Every receptor/pathway readout does not move together. Appetite satiety/fullness and inflammatory responses include nulls; comparator cell-specific receptor deletions dissociate glycemia from weight. Additional downgrade: False.

Therapeutic effect misread as mechanism proof. Drug efficacy does not prove each receptor is necessary in humans.

Replication confused with independence. Multiple retatrutide RCTs and phase 2 secondary reports do not automatically constitute separate causal lines.

Selective generalization. Neither model superiority nor class-product analyses establish clinical retatrutide superiority or the quality of every vial.

Confirmation by biomarker. Lipid and metabolite improvements do not prove hard cardiovascular outcomes.

Scope fitted to outcome. Eligibility/dose/horizon are retained from enrollment; low-dose/null participants are not removed as nonresponders.

Adversarial steelman: above, then below

Ζ could be defended from replicated clinical RCTs and mouse receptor perturbations; the positive effect is substantial and consistent. The strongest version would add a retatrutide-specific independent withdrawal or validated mechanistic prediction excluding initiation-trial failure modes.

Δ could be defended because the first trial is unambiguous but exact component mechanism and broader safety are unresolved. That would understate multiple prespecified human contexts/doses and would confuse missing receptor necessity with absence of the registered drug-sufficiency effect.

Reject Ζ because replication and different outcome readouts are not independent causal lines, and class withdrawal cannot be loaned to retatrutide. Reject Δ because positive constrained clinical causality is established across predefined trial contexts with interpretable dose/control boundaries. Retain Ε Moderate.

Final score, causal direction and M/S/D

The registered primary subclaim SC2 supports Ε with Moderate confidence. Retatrutide causes substantial weight loss under supervised trial conditions. Human receptor partition, superiority to modern active comparators and equivalence of online vials require separate evidence. Multiple trials replicate the pharmacological effect; they do not automatically constitute independent causal lines under the frozen shared-failure definition.

Steps 1–2 do not fit because administered drug precedes and causally changes the weight-loss response. Step 3 requires prevention/delay on removal, initiation on engagement and rate limitation; retatrutide-specific withdrawal and rate limitation have not all been demonstrated. Step 4 requiredness is not shown because lifestyle and other drugs can reduce weight. Step 5 therefore applies to maintenance/modification of the upstream obesity trajectory; this mandatory coarse role label does not assert that drug-caused weight loss is merely correlational.

Momentum: Decisive work underway. TRIUMPH registrational and Outcomes programme; registered active-comparison studies and outcomes trials could address modern comparator and hard-event boundaries. Published TRIUMPH-1/2 results now extend evidence to 80 weeks; protocol or press release is not counted as completed outcome data.

Stability: Uncertain. Direct modern-comparator results and retatrutide-specific withdrawal/long-term outcomes could improve comparative scope and independence; adverse-event, discontinuation or durability findings could narrow the clinical context. These can move different subclaims in different directions.

Divergence: Contested. No survey of competent-reader inferred ladder levels was performed; supply publicity is not a field-wide scientific consensus. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

A blinded randomized retatrutide versus contemporary obesity-dose dual/GLP1 comparator trial, matched eligibility, lifestyle support and treatment-regimen estimand over 72 weeks, with a prespecified retatrutide continuation-versus-withdrawal phase in baseline-defined tolerators and independent weight/function assessment. Add human energy-expenditure/intake/body-composition substudy without interpreting correlations as receptor necessity.

Readout: Prespecified percent weight change, ≥5% responders, objective strength/function and adverse-event/discontinuation outcomes; exposure and intake/energy expenditure separately. Controls: Comparable dose escalation, verified formulations, matched follow-up/estimands and lifestyle support; independent assessor, missingness sensitivity and both randomized and tolerator populations reported. Supporting: Greater clinically meaningful weight/function benefit under comparable conditions plus intervention-sensitive retatrutide maintenance under an independently assessed withdrawal contrast would strengthen comparative and causal-line claims. Falsifying: No matched active advantage, poorer tolerated effectiveness or lack of maintenance sensitivity would narrow SC3 or maintenance inference while preserving any confirmed placebo-controlled initiation benefit.

KNOWLEDGE GAPS

Direct matched retatrutide versus modern obesity-dose semaglutide/tirzepatide superiority with comparable estimands and durability.

Retatrutide-specific withdrawal/rechallenge and long-term weight/function maintenance rather than class extrapolation.

Human contribution of each receptor at measured therapeutic exposure, including energy expenditure and intake partition.

Hard cardiovascular/renal outcomes and longer safety follow-up; surrogate lipid and inflammation analyses are insufficient.

Muscle strength/function and clinically important composition outcomes, with DXA missingness disclosed.

Independent identified retatrutide supply-batch quality and product-linked clinical evidence; no assay result from semaglutide characterizes every retatrutide vial.

REVIEWER NOTES

60 original reports were examined via original abstracts/status metadata; selected Methods/Results from 5 reports were also read and receipted. Most complete trial papers/supplements were not audited, including the latest large retatrutide trial bodies. The sixty records include comparator/mechanistic/supply reports and secondary original analyses; they are not sixty retatrutide trials. Consensus Pro browser supports aspect cross-checks and gaps/timelines, with documented omission of newly published TRIUMPH results. Scite monthly quota was already exhausted. No independent blinded adjudication or clinical peer review is claimed. Direct retatrutide coverage comprises 10 reports (including one discovery/early-human report, five phase 2/3 primary efficacy reports and four secondary original analyses); 50 additional reports examine comparator or mechanism/supply questions. These records are not 60 retatrutide trials. Coordinating source checks retained Ε/Moderate for trial-defined weight loss. Original 2023 phase 2, 2026 TRIUMPH1/2 and preclinical LY3437943 abstracts were examined for direction, population, dose and horizon; modern direct comparator superiority and supply equivalence remain separate. Recent TRIUMPH papers were missed by Consensus, not absent from the literature. Confidence reflects limited independent research programmes and mechanistic partition as well as access limits.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Original abstract agrees with 338 randomized adults, 24-week primary and 48-week secondary weights and high-dose 5% responders. This supports trial efficacy, not a modern active-comparator superiority claim. Full trial Methods/supplement were not fully audited. Original PMID37366315.

Original abstract confirms 537 participants and treatment-regimen weight change −11.5% to −15.3% versus −2.6% placebo. The primary endpoint is HbA1c and entry BMI ≥23; whole-cohort weights do not exactly estimate the preregistered obesity/overweight subset. Original PMID42250575.

Original PMID42814954 confirms peer-reviewed 29 September 2026 results, 2339 randomized participants and 80-week treatment-regimen weights up to −25.0% versus −3.9% placebo. Provider corpus omission is not absence of publication. 80 weeks is longer-horizon corroboration beyond our registered 24–72 weeks. The indexed OSA sign inconsistency is flagged without repeating that number. Original PMID42814954.

Original PMID42810372 confirms 1152 randomized adults with BMI ≥27 and T2D, multiple-imputation treatment-regimen weight results at 80 weeks and tolerability signals. This result is available before cutoff; a provider gap cannot be called a research gap. Original PMID42810372.

Original randomized double-dummy phase 2 report confirms 36-week retatrutide weight loss beyond dulaglutide 1.5 mg at doses ≥4 mg, but cannot establish superiority over obesity-dose semaglutide/tirzepatide. Original PMID37385280.

Selected original Methods/Results retain self-reported higher-dose hunger effects, but satiety/fullness and aggregate appetite-to-weight correlations are often null. These are the same phase 2 participants, not a new trial or proof of receptor-specific mediation. Original PMID40916752.

Selected original body confirms post-hoc phase 2 analyses and exclusion of post-discontinuation/rescue samples. Inflammation contrasts are nonsignificant in T2D but some are positive in non-diabetes. Surrogates are not hard cardiovascular outcomes or independent clinical causal lines. Original PMID42608321.

Our original class-product testing is semaglutide, not retatrutide, and highest-risk vendor sampling is limited. Results report upper-bound endotoxin values for two samples and an elevated measured value for one despite broader abstract wording. Such data establish failure modes, not every retatrutide vial's quality. Original PMID39509151.

Original 2025 retatrutide DXA substudy exists and shows higher-dose fat-mass reduction, but only 103 completed both scans. Lean-mass proportions do not prove muscle function or absence of sarcopenia; this same phase 2 trial does not create an independence line. Original PMID40609566.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Retatrutide: Clinical Weight Loss and Supply Claims

Selected publication milestones, not an exhaustive history or discovery priority claim.

2013 — Dual-incretin translational experiments establish alternative receptor architectures before retatrutide. Original PMID24174327.

2013 — Glucagon/FGF21 genetic perturbation separates some weight/energy effects from glucose effects. Original PMID23305646.

2022 — LY3437943 discovery combines receptor/mouse perturbation and early human exposure/weight observations. Original PMID35985340.

2023 — Randomized phase 2 obesity weight efficacy demonstrated through 48 weeks. Original PMID37366315.

2023 — Randomized phase 2 T2D trial adds dulaglutide active comparison and dose boundaries. Original PMID37385280.

2025 — A direct tirzepatide-versus-semaglutide comparison demonstrates why head-to-head and cross-trial claims differ. Original PMID40353578.

2025 — Retatrutide DXA body-composition substudy published with missingness limits. Original PMID40609566.

2026 — 40-week retatrutide diabetes phase 3 report published with weight a secondary endpoint. Original PMID42250575.

2026 — 29 September 2026: TRIUMPH-1 reports 80-week obesity weight and clinical subgroup outcomes. Original PMID42814954.

2026 — 29 September 2026: TRIUMPH-2 reports 80-week weight efficacy in obesity with T2D. Original PMID42810372.

Research gaps

Direct matched retatrutide versus modern obesity-dose semaglutide/tirzepatide superiority with comparable estimands and durability.

Retatrutide-specific withdrawal/rechallenge and long-term weight/function maintenance rather than class extrapolation.

Human contribution of each receptor at measured therapeutic exposure, including energy expenditure and intake partition.

Hard cardiovascular/renal outcomes and longer safety follow-up; surrogate lipid and inflammation analyses are insufficient.

Muscle strength/function and clinically important composition outcomes, with DXA missingness disclosed.

Independent identified retatrutide supply-batch quality and product-linked clinical evidence; no assay result from semaglutide characterizes every retatrutide vial.

Boundary experiment

A blinded randomized retatrutide versus contemporary obesity-dose dual/GLP1 comparator trial, matched eligibility, lifestyle support and treatment-regimen estimand over 72 weeks, with a prespecified retatrutide continuation-versus-withdrawal phase in baseline-defined tolerators and independent weight/function assessment. Add human energy-expenditure/intake/body-composition substudy without interpreting correlations as receptor necessity.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks. All 60 REFERENCES PMIDs were verified against PubMed metadata for first author, title, journal and year; 60/60 resolve to the stated record and none carries a retraction or expression of concern. The six linked correction notices (PMID 38409593, 38913535, 38945123, 39245214, 41932351, 42242249) were each confirmed to be a Published Erratum and are correctly recorded in the parent row's status flags rather than given their own numbered source. Eleven load-bearing claims were spot-checked against original abstracts or, where the package holds full text, against the original Results: Jastreboff phase 2 obesity (37366315) 338 randomized adults with 24-week primary and 48-week secondary weight outcomes; Rosenstock phase 2 T2D (37385280) 36 weeks with a dulaglutide 1.5 mg active arm; TRANSCEND-T2D-1 (42250575) 537 randomized, HbA1c primary, BMI ≥23 entry, bodyweight −11.5% to −15.3% versus −2.6% placebo at 40 weeks; TRIUMPH-1 (42814954) 2339 randomized without diabetes, −17.6%/−23.7%/−25.0% versus −3.9% placebo at 80 weeks, published 29 September 2026, and the apnea-hypopnea figure in the indexed abstract does carry an inconsistent sign, which the review correctly flags without reproducing; TRIUMPH-2 (42810372) 1152 randomized with BMI ≥27 and T2D, multiple-imputation treatment-regimen estimand at week 80, published 29 September 2026; SURMOUNT-5 (40353578) tirzepatide versus semaglutide at 72 weeks with no retatrutide arm; Coskun LY3437943 (35985340) receptor assays plus obese-mouse and single-ascending-dose human data; NN1177 (37690519) where the published safety signals precluded further clinical development; Ashraf (39509151) online semaglutide test purchases; Sedensky (42541373) 20 adults completing 15 of 34 grey-market preparation steps correctly; Coskun DXA substudy (40609566). All were accurately attributed for direction of effect, species, design and sample size. Scoring logic was re-derived: the pre-registered aggregation rule (primary-subclaim, SC2) is applied as written, the alternatives are reported (weakest-link Α, scope-matched Ε), SC2's scope is the central claim's scope so no scope-matched misreading arises, and the independence refusal that keeps the level at Ε rather than Ζ follows the framework text directly ("three replications of one line make a confident Ε, not a Ζ").

Findings

Rejected findings (checked, no change)

1. Ε rather than Ζ for SC2. Argued for Ζ: phase 2 and two phase 3 trials in distinct populations, plus receptor-level mouse work, is a lot of evidence. Rejected: the framework's independence test is shared failure, replication adds confidence rather than a line, and mouse receptor perturbation does not address the registered human clinical claim. The framework states directly that replications of one line make a confident Ε, not a Ζ. Level and Moderate confidence retained.
2. Ε as a scope-restricted letter setting the headline. The central claim is itself registered to trial-eligible adults, so SC2's scope matches it; the usual objection to an Ε subclaim setting a broadly scoped headline does not apply here.
3. Causal role "reinforcing / stabilizing factor". Primary driver was considered: the drug initiates the weight-loss response. Rejected because step 3 of the derivation requires prevention or delay on removal and rate limitation as well, and no retatrutide-specific withdrawal trial exists; the derivation is written out step by step in the review and lands defensibly at step 5.
4. Momentum "Decisive work underway". The required artifact names the TRIUMPH registrational and outcomes programme and the registered active-comparison studies, which is a real named programme rather than boilerplate.
5. Horizon handling. The 80-week TRIUMPH results sit outside the registered 24-72-week gate and are treated as corroboration rather than used to redefine the gate retrospectively. Correct, and the alternative would be scope fitted after the result.
6. SC4 at Α. Checked both directions. The review neither asserts that grey-market vials are equivalent nor asserts that they are uniformly dangerous; it grades the positive equivalence proposition as speculative and states explicitly that absence of evidence is not a measurement of every product. The analytical and usability findings are reported as failure modes in semaglutide products, not transferred to retatrutide. No change.
7. Citation-year and title conventions. No reference year deviated from PubMed by more than one; PubMed's dropping of superscripts (NAD+, BMI units) is a field artifact. No collective-author rendering defect is present in this reference list.

Residual limitations

Five of sixty sources were examined beyond abstract depth, and the two largest retatrutide trial bodies were not audited in full, so the 80-week figures rest on abstracts. No retatrutide product from the grey market has been analytically tested or linked to clinical outcomes in any examined source, so SC4 remains an evidentiary gap rather than a reassurance in either direction. No direct randomized comparison against obesity-dose semaglutide or tirzepatide exists, so the comparative question that most readers will ask remains unanswered.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Jastreboff AM, Kaplan LM, Frías JP et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. 2023. PMID 37366315. DOI: 10.1056/NEJMoa2301972. Access: abstract_metadata. Study: RETAT-NCT04881760.

2. Coskun T, Wu Q, Schloot NC et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology. 2025. PMID 40609566. DOI: 10.1016/S2213-8587(25)00092-0. Access: abstract_metadata. Study: RETAT-NCT04867785.

3. Kanu C, Boye KS, Poon JL et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, obesity & metabolism. 2025. PMID 40916752. DOI: 10.1111/dom.70097. Access: full_text_partial. Study: RETAT-NCT04867785.

4. Bajaj HS, Welch M, Shah P et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2026. PMID 42250575. DOI: 10.1016/S0140-6736(26)00967-0. Access: abstract_metadata. Study: RETAT-NCT06354660.

5. Bellido V, le Roux CW, Ekinci EI et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026. PMID 42810372. DOI: 10.1016/S0140-6736(26)01861-1. Access: abstract_metadata. Study: RETAT-NCT05929079.

6. Rosenstock J, Frias J, Jastreboff AM et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England). 2023. PMID 37385280. DOI: 10.1016/S0140-6736(23)01053-X. Access: abstract_metadata. Study: RETAT-NCT04867785.

7. Pearson MJ, Willency JA, Lin Y et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2026. PMID 42135195. DOI: 10.1210/clinem/dgag201. Access: abstract_metadata. Study: RETAT-PHASE2-POOLED.

8. Ruotolo G, Harris C, Lin Y et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, obesity & metabolism. 2026. PMID 42608321. DOI: 10.1111/dom.71200. Access: full_text_partial. Study: RETAT-PHASE2-POOLED.

9. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA internal medicine. 2024. PMID 38976257. DOI: 10.1001/jamainternmed.2024.2525. Access: abstract_metadata. Study: PMID38976257.

10. Ciudin A, Johansson E, Zimner-Rapuch S et al. Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes. Diabetes, obesity & metabolism. 2025. PMID 40537987. DOI: 10.1111/dom.16508. Access: abstract_metadata. Study: SURMOUNT2-STEP2-ITC.

11. Hankosky ER, He X, Malik R et al. Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison. Diabetes, obesity & metabolism. 2025. PMID 40321113. DOI: 10.1111/dom.16401. Access: abstract_metadata. Study: SURMOUNT2-STEP2-ITC.

12. Kitamoto T, Yoshino M, Shingaki T et al. Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial. Current medical research and opinion. 2026. PMID 42434924. DOI: 10.1080/03007995.2026.2695047. Access: abstract_metadata. Study: SURMOUNT5-NCT05822830.

13. Cetiner S. Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study. Diabetes, metabolic syndrome and obesity : targets and therapy. 2026. PMID 41938643. DOI: 10.2147/DMSO.S594898. Access: abstract_metadata. Study: PMID41938643.

14. Willard FS, Douros JD, Gabe MB et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight. 2020. PMID 32730231. DOI: 10.1172/jci.insight.140532. Access: abstract_metadata. Study: PMID32730231.

15. Ravussin E, Sanchez-Delgado G, Martin CK et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell metabolism. 2025. PMID 40203836. DOI: 10.1016/j.cmet.2025.03.011. Access: abstract_metadata. Study: PMID40203836.

16. Regmi A, Aihara E, Christe ME et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell metabolism. 2024. PMID 38878772. DOI: 10.1016/j.cmet.2024.05.010. Access: abstract_metadata. Study: PMID38878772.

17. Samms RJ, Christe ME, Collins KA et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. The Journal of clinical investigation. 2021. PMID 34003802. DOI: 10.1172/JCI146353. Access: abstract_metadata. Study: PMID34003802.

18. Knerr PJ, Mowery SA, Douros JD et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Molecular metabolism. 2022. PMID 35809773. DOI: 10.1016/j.molmet.2022.101533. Access: full_text_partial. Study: PMID35809773.

19. Liskiewicz A, Khalil A, Liskiewicz D et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nature metabolism. 2023. PMID 37946085. DOI: 10.1038/s42255-023-00931-7. Access: abstract_metadata. Study: PMID37946085.

20. Finan B, Ma T, Ottaway N et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science translational medicine. 2013. PMID 24174327. DOI: 10.1126/scitranslmed.3007218. Access: abstract_metadata. Study: PMID24174327.

21. El K, Douros JD, Willard FS et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature metabolism. 2023. PMID 37277609. DOI: 10.1038/s42255-023-00811-0. Access: abstract_metadata. Study: PMID37277609.

22. McMorrow HE, Cohen AB, Lorch CM et al. Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice. The Journal of clinical investigation. 2025. PMID 40857106. DOI: 10.1172/JCI186652. Access: abstract_metadata. Study: PMID40857106.

23. Zhao F, Zhou Q, Cong Z et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nature communications. 2022. PMID 35217653. DOI: 10.1038/s41467-022-28683-0. Access: abstract_metadata. Study: PMID35217653.

24. Schreier PCF, Beyerle P, Boulassel S et al. GLP-1/GIP/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and Gαq signalling pathway in mice. Diabetologia. 2025. PMID 40924112. DOI: 10.1007/s00125-025-06525-0. Access: abstract_metadata. Study: PMID40924112.

25. Wean J, Kowalsky AH, Laker R et al. Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss. Molecular metabolism. 2025. PMID 39612941. DOI: 10.1016/j.molmet.2024.102074. Access: abstract_metadata. Study: PMID39612941.

26. Malavazos AE, Iacobellis G, Dozio E et al. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. European journal of preventive cardiology. 2023. PMID 36799940. DOI: 10.1093/eurjpc/zwad050. Access: abstract_metadata. Study: PMID36799940.

27. Akindehin S, Liskiewicz A, Liskiewicz D et al. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice. Molecular metabolism. 2024. PMID 38492844. DOI: 10.1016/j.molmet.2024.101915. Access: abstract_metadata. Study: PMID38492844.

28. Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism. 2022. PMID 35441470. DOI: 10.1111/dom.14725. Access: abstract_metadata. Study: STEP1-NCT03548935.

29. Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID 33755728. DOI: 10.1001/jama.2021.3224. Access: abstract_metadata. Study: STEP4-NCT03548987.

30. Kosiborod MN, Bhatta M, Davies M et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, obesity & metabolism. 2023. PMID 36200477. DOI: 10.1111/dom.14890. Access: abstract_metadata. Study: STEP1-4-POOLED.

31. Wilkinson L, Holst-Hansen T, Laursen PN et al. Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity. Obesity (Silver Spring, Md.). 2023. PMID 37605636. DOI: 10.1002/oby.23842. Access: abstract_metadata. Study: STEP1-4-5-POOLED.

32. Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021. PMID 33567185. DOI: 10.1056/NEJMoa2032183. Access: abstract_metadata. Study: STEP1-NCT03548935.

33. Wharton S, Freitas P, Hjelmesæth J et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025. PMID 40961952. DOI: 10.1016/S2213-8587(25)00226-8. Access: abstract_metadata. Study: PMID40961952.

34. Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024. PMID 39476339. DOI: 10.1056/NEJMoa2403664. Access: abstract_metadata. Study: PMID39476339.

35. Davies M, Færch L, Jeppesen OK et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021. PMID 33667417. DOI: 10.1016/S0140-6736(21)00213-0. Access: abstract_metadata. Study: STEP2-NCT03552757.

36. Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022. PMID 36216945. DOI: 10.1038/s41591-022-02026-4. Access: abstract_metadata. Study: PMID36216945.

37. Wadden TA, Bailey TS, Billings LK et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. PMID 33625476. DOI: 10.1001/jama.2021.1831. Access: abstract_metadata. Study: PMID33625476.

38. Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022. PMID 35015037. DOI: 10.1001/jama.2021.23619. Access: abstract_metadata. Study: PMID35015037.

39. Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2023. PMID 37622681. DOI: 10.1056/NEJMoa2306963. Access: abstract_metadata. Study: PMID37622681.

40. Kosiborod MN, Petrie MC, Borlaug BA et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. The New England journal of medicine. 2024. PMID 38587233. DOI: 10.1056/NEJMoa2313917. Access: abstract_metadata. Study: PMID38587233.

41. McGowan BM, Bruun JM, Capehorn M et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. The lancet. Diabetes & endocrinology. 2024. PMID 39089293. DOI: 10.1016/S2213-8587(24)00182-7. Access: abstract_metadata. Study: PMID39089293.

42. Lingvay I, Bergenheim SJ, Buse JB et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025. PMID 40961953. DOI: 10.1016/S2213-8587(25)00225-6. Access: abstract_metadata. Study: PMID40961953.

43. Wharton S, Calanna S, Davies M et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism. 2022. PMID 34514682. DOI: 10.1111/dom.14551. Access: abstract_metadata. Study: STEP1-2-3-4-POOLED.

44. Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine. 2025. PMID 39536238. DOI: 10.1056/NEJMoa2410819. Access: abstract_metadata. Study: SURMOUNT1-NCT04184622.

45. Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022. PMID 35658024. DOI: 10.1056/NEJMoa2206038. Access: abstract_metadata. Study: SURMOUNT1-NCT04184622.

46. Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID 38078870. DOI: 10.1001/jama.2023.24945. Access: abstract_metadata. Study: SURMOUNT4-NCT04660643.

47. Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine. 2025. PMID 40353578. DOI: 10.1056/NEJMoa2416394. Access: abstract_metadata. Study: SURMOUNT5-NCT05822830.

48. Zhao L, Cheng Z, Lu Y et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. PMID 38819983. DOI: 10.1001/jama.2024.9217. Access: abstract_metadata. Study: PMID38819983.

49. Horn DB, Aronne LJ, Wharton S et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England). 2026. PMID 42119587. DOI: 10.1016/S0140-6736(26)00656-2. Access: abstract_metadata. Study: PMID42119587.

50. Wadden TA, Chao AM, Machineni S et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature medicine. 2023. PMID 37840095. DOI: 10.1038/s41591-023-02597-w. Access: abstract_metadata. Study: PMID37840095.

51. Kadowaki T, Kiyosue A, Shingaki T et al. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. The lancet. Diabetes & endocrinology. 2025. PMID 40031941. DOI: 10.1016/S2213-8587(24)00377-2. Access: abstract_metadata. Study: PMID40031941.

52. Friedrichsen MH, Endahl L, Kreiner FF et al. Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity. Molecular metabolism. 2023. PMID 37690519. DOI: 10.1016/j.molmet.2023.101801. Access: abstract_metadata. Study: PMID37690519.

53. Alba M, Yee J, Frustaci ME et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study. Clinical obesity. 2021. PMID 33475255. DOI: 10.1111/cob.12432. Access: abstract_metadata. Study: PMID33475255.

54. Di Prospero NA, Yee J, Frustaci ME et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study. Clinical obesity. 2021. PMID 33475251. DOI: 10.1111/cob.12433. Access: abstract_metadata. Study: PMID33475251.

55. Jastreboff AM, Kaplan LM, Davies MJ et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England journal of medicine. 2026. PMID 42814954. DOI: 10.1056/NEJMoa2604169. Access: abstract_metadata. Study: RETAT-NCT05929066.

56. Coskun T, Urva S, Roell WC et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell metabolism. 2022. PMID 35985340. DOI: 10.1016/j.cmet.2022.07.013. Access: abstract_metadata. Study: PMID35985340.

57. Ashraf AR, Mackey TK, Vida RG et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of medical Internet research. 2024. PMID 39509151. DOI: 10.2196/65440. Access: full_text_partial. Study: SEMAGLUTIDE-ONLINE-PURCHASES-2023.

58. Hach M, Engelund DK, Mysling S et al. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharmaceutical research. 2024. PMID 39379664. DOI: 10.1007/s11095-024-03771-6. Access: abstract_metadata. Study: PMID39379664.

59. Sedensky A, Nuzi K, Nolan L et al. Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription. Public health reports (Washington, D.C. : 1974). 2026. PMID 42541373. DOI: 10.1177/00333549261464876. Access: abstract_metadata. Study: PMID42541373.

60. Habegger KM, Stemmer K, Cheng C et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes. 2013. PMID 23305646. DOI: 10.2337/db12-1116. Access: full_text_partial. Study: PMID23305646.

Source-specific evidence cards

[1] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Shows: A 338-adult randomized placebo trial shows dose-related retatrutide weight loss through 48 weeks, with high-dose responder rates exceeding the registered 5% benchmark.

Does not show: Placebo efficacy is not superiority to semaglutide or tirzepatide; adverse GI events and heart-rate changes remain relevant.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[2] Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.

Shows: Retatrutide reduces DXA fat mass in a randomized T2D phase 2 substudy, with positive higher-dose contrasts.

Does not show: Only 103 participants completed treatment and both DXA scans; lean mass is not muscle strength, and this shares NCT04867785 rather than supplying a new trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[3] Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.

Shows: Randomized phase 2 appetite analysis finds higher-dose hunger and disinhibition reductions and modest eating-inventory correlations with weight change.

Does not show: Satiety/fullness and aggregate appetite-to-weight correlations are often null; self-report correlations do not isolate receptor mediation; same phase 2 trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS AND METHODS:paragraph0, 1:MATERIALS AND METHODS:paragraph2, 4:RESULTS:paragraph0, 4:RESULTS:paragraph2, 4:RESULTS:paragraph5, 4:RESULTS:paragraph7, 4:RESULTS:paragraph14. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[4] Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

Shows: TRANSCEND-T2D-1 randomizes 537 adults and reports treatment-regimen weight loss of 11.5–15.3% versus 2.6% placebo at 40 weeks.

Does not show: Primary endpoint is HbA1c; entry BMI ≥23 includes participants outside the registered obesity/overweight scope, so whole-cohort means are corroboration with a population limitation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[5] Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Shows: TRIUMPH-2 shows substantial placebo-adjusted weight loss in 1152 adults with BMI ≥27 and T2D using multiple-imputation treatment-regimen analyses.

Does not show: The 80-week endpoint extends beyond the registered 24–72-week horizon; no modern active comparator, and dysesthesia/hypotension/discontinuations qualify safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[6] Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

Shows: Randomized double-dummy phase 2 T2D trial shows higher-dose weight loss beyond placebo and dulaglutide 1.5 mg through 36 weeks.

Does not show: Dulaglutide 1.5 mg is not modern obesity-dose semaglutide or tirzepatide; six inadvertent enrollments excluded from efficacy analyses; lower dose weak/null.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[7] Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.

Shows: Original phase 2 metabolomics secondary analyses detect fatty-acid oxidation and insulin-resistance clusters associated with retatrutide.

Does not show: Mediation models and metabolic proxies do not establish human receptor-specific energy-expenditure causality; shares both phase 2 datasets.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[8] Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.

Shows: Original phase 2 post-hoc lipid/lipoprotein analyses show treatment-associated shifts in two populations; inflammation changes differ by diabetes status.

Does not show: Post-discontinuation/rescue samples excluded; no hard cardiovascular outcomes, and lipid/inflammation changes are not independent new causal trials.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Material and Methods:paragraph0, 1:Material and Methods:paragraph2, 1:Material and Methods:paragraph3, 2:Results:paragraph0, 2:Results:paragraph12, 2:Results:paragraph14. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[9] Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

Shows: Propensity-matched dispensing/EHR cohort associates tirzepatide with greater on-treatment weight loss than semaglutide.

Does not show: Selection, dosing, discontinuation and missing weight measurements remain; neither arm receives retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[10] Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.

Shows: Bucher indirect reanalysis compares SURMOUNT-2 and STEP2 and estimates larger weight reduction with tirzepatide.

Does not show: Inter-trial comparability assumptions do not create randomized head-to-head allocation; same underlying studies as PMID40321113; no retatrutide arm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[11] Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.

Shows: Original indirect reanalysis estimates larger tirzepatide weight reductions than semaglutide, with sensitivity analyses.

Does not show: Not an independent RCT despite indexed publication tags; shares SURMOUNT-2 and STEP2 and does not test retatrutide superiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[12] Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.

Shows: SURMOUNT-5 subgroup with baseline Japanese obesity-disease criteria preserves tirzepatide advantage over semaglutide.

Does not show: Subset of the same trial, not an extra causal line; global enrollment criteria and no retatrutide limit transfer.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[13] Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.

Shows: Retrospective obesity cohort associates tirzepatide with larger weight reduction than semaglutide/liraglutide.

Does not show: Nonrandom treatment allocation and treatment persistence selection; cannot rank retatrutide or measure receptor necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[14] Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

Shows: Original receptor signaling and primary-islet experiments show imbalanced GIPR/GLP1R engagement and GLP1R signaling bias for tirzepatide.

Does not show: This dual agonist demonstrates an alternative receptor architecture; occupancy estimates are not measured retatrutide target engagement in patients.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[15] Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.

Shows: Tirzepatide phase 1 human and pair-fed mouse studies find fat oxidation and appetite effects, but metabolic adaptation effects differ between species.

Does not show: Human lack of adaptation effect challenges simple mouse-to-human energy-expenditure transfer; different drug cannot falsify retatrutide weight efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[16] Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.

Shows: Original human adipocyte/mouse assays show context-dependent GIPR effects on glucose uptake, lipid release and clearance.

Does not show: Tirzepatide/GIPR agonists, not clinical retatrutide; linked correction PMID38945123 is attached and revised numerical details were not available.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 38945123. Subclaims: SC1.

[17] GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.

Shows: Glp1r-null mice and selective GIP agonism separate a weight-independent insulin-sensitization component of tirzepatide.

Does not show: Glucose disposal and BCAA changes do not demonstrate human weight loss or the necessity of retatrutide glucagon activity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[18] Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.

Shows: Optimized triagonist compound 16 outperforms equimolar tirzepatide in DIO mice and raises indirect-calorimetry energy expenditure with similar intake suppression.

Does not show: Compound 16 is not retatrutide; male-mouse exposures and whole-body calorimetry do not establish clinical superiority or partition every receptor.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 2:Results:paragraph9, 2:Results:paragraph11. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[19] Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.

Shows: Vgat-Gipr deletion removes enhanced weight/intake reduction from long-acting GIP and a dual coagonist in DIO male mice.

Does not show: Different peptide and cell-specific developmental knockout do not directly establish retatrutide human mechanism or all GIPR cell populations.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[20] Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Shows: Original dual-incretin development demonstrates metabolic effects across rodents, primates and early humans.

Does not show: This alternative GIP/GLP1 architecture shows triple agonism is not necessary for weight benefit; no matched human retatrutide comparison.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[21] The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.

Shows: Human-islet receptor antagonism shows tirzepatide insulin secretion depends on both incretin receptors, while mouse potency favors GLP1R.

Does not show: Insulin secretion is not clinical bodyweight reduction; species-specific potency cautions against simple receptor transfer to retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[22] Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice.

Shows: Fiber photometry and incretin perturbations show pharmacological analogs inhibit AgRP hunger neurons, with endogenous GIP specificity.

Does not show: Neural activity and short-term intake do not alone prove the retatrutide clinical mechanism or contribution of glucagon.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[23] Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.

Shows: Cryo-EM structures resolve multiplexed receptor binding by tirzepatide and peptide 20.

Does not show: Reconstituted engineered complexes are not living-patient occupancy or proof that three components jointly cause clinical superiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[24] GLP-1/GIP/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and Gαq signalling pathway in mice.

Shows: IUB447 knockout/antagonist assays identify GLP1R–Gαq–TRPM5-centered insulin secretion; individual Gipr/Gcgr removal leaves GSIS enhancement.

Does not show: Different triagonist and glucose endpoint cannot refute retatrutide weight loss; shows triagonist label need not imply equal receptor necessity for every outcome.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[25] Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss.

Shows: Whole-body and GABAergic GIPR knockout increase GLP1-alone weight effects while eliminating dual-agonist enhancement and anti-aversion.

Does not show: Both agonism and removal can yield benefit; cell/agent-specific mechanism, not proof all GIPR strategies act identically.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[26] Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.

Shows: Original 33-patient surgical tissue assays report incretin/glucagon receptor expression in epicardial fat.

Does not show: Expression and transcript associations are presence evidence, not functional drug engagement, weight causality or cardiovascular protection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[27] Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.

Shows: Lepr-Gipr deletion removes enhanced glycemic effects of dual agonism but leaves bodyweight and food-intake effects intact.

Does not show: Cell-specific null maps receptor-function boundaries; glucose and weight outcomes are different, and retatrutide was not tested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[28] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.

Shows: STEP1 extension reports substantial regain after withdrawal of semaglutide and lifestyle support.

Does not show: Exploratory selected extension with joint lifestyle withdrawal; same STEP1 trial and different drug, not retatrutide withdrawal proof.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[29] Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Shows: STEP4 randomized continuation versus withdrawal causally separates semaglutide weight maintenance in run-in tolerators.

Does not show: Enrollment to randomization selects tolerated exposure; this comparative class result cannot establish retatrutide off-treatment durability.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[30] Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.

Shows: Original STEP1/4 exploratory analyses report cardiometabolic changes that worsen after semaglutide withdrawal.

Does not show: Shared study participants and surrogate risk metrics cannot supply independent retatrutide efficacy or cardiovascular benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[31] Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.

Shows: STEP1/4/5 post-hoc risk-score analyses track improvements with semaglutide and deterioration after withdrawal.

Does not show: Estimated 10-year risk is not observed 10-year diabetes incidence; secondary analysis shares trials and excludes retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[32] Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Shows: STEP-1 randomizes 1961 adults and demonstrates semaglutide weight loss beyond lifestyle/placebo at 68 weeks.

Does not show: Different molecule and trial population; percentages must not be ranked as a randomized retatrutide comparison.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[33] Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.

Shows: STEP UP directly compares semaglutide 7.2 mg with 2.4 mg/placebo and reports additional weight loss plus more dysesthesia.

Does not show: No retatrutide arm; higher-dose comparator benefits and adverse events change the comparison question.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[34] Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.

Shows: STEP-9 randomizes 407 adults with knee OA/obesity and improves weight and pain with semaglutide.

Does not show: Disease-specific pain scales and population cannot be directly compared with TRIUMPH subgroup outcomes or establish triple receptor necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[35] Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Shows: STEP-2 placebo-controlled diabetes/obesity trial establishes semaglutide weight loss and 5% responder benefits.

Does not show: Diabetes modifies population/estimand, and no retatrutide arm; parent dataset for indirect comparison analyses.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[36] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.

Shows: STEP-5 demonstrates sustained semaglutide weight benefit at 104 weeks.

Does not show: Longer treatment efficacy is not off-treatment durability or retatrutide efficacy; predominantly White/female participants.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[37] Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

Shows: STEP3 shows semaglutide adds weight benefit to intensive behavioral therapy and initial low-calorie diet.

Does not show: Co-intervention differs from other obesity trials, precluding naive cross-trial superiority; no retatrutide arm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[38] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Shows: STEP8 randomized active-drug comparison establishes greater semaglutide than liraglutide weight loss.

Does not show: Active comparison is open-label and titration/tolerability rules differ; neither regimen is retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[39] Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

Shows: STEP-HFpEF improves symptoms, walk distance and weight with semaglutide in obesity-relatedHFpEF.

Does not show: Specific heart-failure population and endpoint do not establish retatrutide event prevention or clinical superiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[40] Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Shows: STEP-HFpEF-DM shows semaglutide weight and functional benefits in obesity-related HFpEF with T2D.

Does not show: Different clinical syndrome and molecule; cannot loan hard cardiac or functional outcomes to retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[41] Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.

Shows: STEP10 establishes semaglutide weight reduction and normoglycemia in baseline prediabetes.

Does not show: Normoglycemia endpoint/duration is not long-term disease prevention or evidence of retatrutide superiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[42] Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.

Shows: STEP UP T2D shows semaglutide 7.2 mg beats placebo for weight loss, with more dysesthesia.

Does not show: No retatrutide arm and linked erratum PMID41932351 limits unaudited detailed numerics.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 41932351. Subclaims: SC3.

[43] Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

Shows: STEP1–4 secondary analyses find semaglutide weight loss both with and without GI events; mediation estimates little GI-mediated loss.

Does not show: GI mediation is model-dependent, not randomized nausea separation; shared parent trials and not retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[44] Tirzepatide for Obesity Treatment and Diabetes Prevention.

Shows: SURMOUNT-1 extended randomized treatment reports sustained tirzepatide weight loss and lower observed diabetes progression over 176 weeks.

Does not show: Same SURMOUNT-1 study as the 72-week report, restricted baseline prediabetes cohort; benefit cannot be transferred to retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[45] Tirzepatide Once Weekly for the Treatment of Obesity.

Shows: SURMOUNT-1 establishes tirzepatide weight loss and responder benefits beyond placebo at 72 weeks.

Does not show: No retatrutide and different dose schedules, estimands and populations from triple-agonist trials.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[46] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

Shows: SURMOUNT4 randomized withdrawal shows weight regain after switch to placebo and maintenance with continued tirzepatide.

Does not show: Open-label run-in selects completers/tolerators, and class withdrawal does not establish retatrutide withdrawal dynamics.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[47] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

Shows: SURMOUNT-5 directly randomizes tirzepatide versus semaglutide and demonstrates greater tirzepatide weight reduction at 72 weeks.

Does not show: Open-label active comparison and dose tolerability differ; this establishes their relationship, not retatrutide superiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[48] Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.

Shows: SURMOUNT-CN demonstrates placebo-controlled tirzepatide weight loss in Chinese adults at 52 weeks.

Does not show: Different drug and regional BMI criteria, and linked erratum PMID38913535 attaches to parent not separate evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 38913535. Subclaims: SC3.

[49] Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

Shows: SURMOUNT-MAINTAIN randomizes continued/reduced-dose tirzepatide versus withdrawal and finds maintenance advantages.

Does not show: Rescue after substantial regain and modified estimand complicate raw comparisons; linked erratum PMID42242249; not retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 42242249. Subclaims: SC3.

[50] Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.

Shows: SURMOUNT3 shows tirzepatide adds further loss after a successful intensive lifestyle run-in.

Does not show: Baseline-to-randomization responders are prespecified selected cohort, not all entrants; linked correction PMID38409593; no retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 38409593. Subclaims: SC3.

[51] Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.

Shows: SURMOUNT-J shows placebo-controlled tirzepatide weight benefits in Japanese obesity-disease patients.

Does not show: Modified ITT excludes a site and national eligibility differs; no retatrutide; generalization remains endpoint/population-specific.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[52] Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.

Shows: Original three NN1177 dual-agonist phase 1 trials show weight loss but safety signals stop development.

Does not show: Different peptide and short trials; linked erratum PMID39245214; efficacy alone does not guarantee safety of polyagonism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 39245214. Subclaims: SC1, SC3.

[53] Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.

Shows: JNJ64565111 dual GLP1/glucagon trial reduces weight versus placebo with greater GI events.

Does not show: No GIP component yet weight benefit, so triple agonism is not necessary for weight loss in general; different molecule does not rank retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[54] Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study.

Shows: JNJ64565111 lowers weight in T2D/obesity but does not improve HbA1c and raises some glucose measures.

Does not show: Weight and glycemic benefit separate; short different-agent trial cannot falsify retatrutide's positive clinical results.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[55] Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

Shows: TRIUMPH-1 randomizes 2339 adults without diabetes and reports treatment-regimen weight reductions up to 25.0% versus 3.9% placebo at 80 weeks.

Does not show: Beyond the registered 24–72-week horizon; no active modern comparator; the original abstract contains an inconsistent OSA sign so that subgroup number is not repeated.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[56] LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

Shows: Original LY3437943 discovery combines functional receptor assays, obese-mouse weight/energy experiments and early human pharmacokinetics/weight signals.

Does not show: Single-dose early human study is not 24–72-week efficacy or receptor-component necessity in humans; compound-specific mechanism needs matched counterfactuals.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[57] Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study.

Shows: Original semaglutide test-purchase study finds mislabeled quantities, measured purity of 7.7-14.37% against a 99% label claim, and endotoxin detected in all three delivered vials, plus nondelivery scams.

Does not show: The highest-risk small-vendor sample, assay purity interpretation and the upper-bound form of two of the three endotoxin values all matter; this is not retatrutide testing or clinical population incidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph7, 1:Methods:paragraph11, 1:Methods:paragraph12, 2:Results:paragraph21, 2:Results:paragraph27, 2:Results:paragraph28, 2:Results:paragraph32. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[58] Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.

Shows: Analytical follow-on semaglutide/liraglutide comparisons detect altered impurities, content, dissolution and predicted immunogenicity/stability.

Does not show: In-silico epitopes and quality changes do not demonstrate clinical harms; commercially available follow-ons are not all online retatrutide vials.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[59] Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription.

Shows: Twenty untrained adults performing simulated grey-market semaglutide tasks make dosing/injection-process errors.

Does not show: Simulation is not actual retatrutide use or measured infection/adverse-event incidence; no instructions reproduced in the review.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[60] Fibroblast growth factor 21 mediates specific glucagon actions.

Shows: Glucagon agonist effects on mouse weight/energy expenditure depend on FGF21 deletion, with acute human FGF21 response to glucagon.

Does not show: Single agonist/mouse knockout and acute biomarker response do not establish human retatrutide glucagon necessity; hyperglycemia can coexist with weight loss.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:RESEARCH DESIGN AND METHODS:paragraph0, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13, 1:RESULTS:paragraph15, 1:RESULTS:paragraph19. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• reader-summary.json
• research-timeline.json
• retatrutide-weight-loss.review.md
• retatrutide-weight-loss.scorecard.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 60 · load-bearing claims: 65 · verified: 65 · unverified: 0 · contradicted: 0 · schema 5.3